We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Iovance Biotherapeutics Inc | NASDAQ:IOVA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.09 | 0.78% | 11.63 | 11.40 | 11.60 | 11.80 | 11.335 | 11.60 | 2,489,461 | 00:54:04 |
| | |
PER SHARE
|
| |
TOTAL
|
| ||||||
Public Offering Price
|
| | | $ | | | | | $ | | | ||
Underwriting Discounts and Commissions(1)
|
| | | $ | | | | | $ | | | ||
Offering to Iovance Biotherapeutics, Inc. before expenses
|
| | | $ | | | | | $ | | | | |
| | | | | | | | | | | | | |
| Jefferies | | |
Goldman Sachs & Co. LLC
|
| |
Wells Fargo Securities
|
|
| | |
Page
|
| |||
Prospectus Supplement | | | | | | | |
| | | | S-ii | | | |
| | | | S-iii | | | |
| | | | S-1 | | | |
| | | | S-7 | | | |
| | | | S-10 | | | |
| | | | S-11 | | | |
| | | | S-15 | | | |
| | | | S-22 | | | |
| | | | S-22 | | | |
| | | | S-22 | | | |
| | | | S-23 | | | |
Prospectus | | | | | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 12 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 22 | | | |
| | | | 24 | | | |
| | | | 26 | | | |
EXPERTS | | | | | 26 | | |
| | | | 26 | | | |
| | | | 27 | | |
UNDERWRITER
|
| |
NUMBER OF
SHARES |
|
Jefferies LLC
|
| |
|
|
Goldman Sachs & Co. LLC
|
| | | |
Wells Fargo Securities, LLC
|
| | | |
Total
|
| | | |
| | | | |
| | |
PER SHARE
|
| |
TOTAL
|
| ||||||||||||||||||
| | |
WITHOUT
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITH
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITHOUT
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITH
OPTION TO PURCHASE ADDITIONAL SHARES |
| ||||||||||||
Public offering price
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
Underwriting discounts and commissions paid by us
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
Proceeds to us, before expenses
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 12 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 22 | | | |
| | | | 24 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 27 | | |
1 Year Iovance Biotherapeutics Chart |
1 Month Iovance Biotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions